Selv om Galvus som tillægsbehandling til insulin gav større fald i HbA1c end placebo, var virkningen for lille til at blive anset for at have klinisk betydning for patienterne.
Although adding Galvus to existing insulin therapy caused a greater reduction in HbA1c levels than placebo, the size of this effect was too small to be considered meaningful for patients.